文献速递临床试验与 GCP流行病学与生物统计

头盔无创通气与经鼻高流量氧疗对COVID-19中重度低氧血症患者无呼吸支持天数的影响:HENIVOT随机临床试验

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该多中心随机临床试验在意大利4个ICU纳入109例COVID-19合并中重度低氧性呼吸衰竭患者,比较头盔无创通气与单纯经鼻高流量氧疗。

核心结论

  • 在COVID-19中重度低氧血症患者中,头盔无创通气与经鼻高流量氧疗相比,28天内无呼吸支持天数无显著差异。
  • 头盔无创通气可显著降低气管插管率并增加28天内无创机械通气天数,但院内死亡率无显著差异。

研究设计与样本

  • 多中心随机临床试验,在意大利4个ICU开展,2020年10月至12月入组,随访至2021年2月11日。
  • 纳入109例COVID-19合并中重度低氧性呼吸衰竭患者(PaO2/FiO2≤200),随机分头盔无创通气组(n=54)与经鼻高流量氧疗组(n=55)。

关键数值与推荐

  • 头盔无创通气参数:呼气末正压10-12 cm H2O,压力支持10-12 cm H2O,持续至少48小时,随后可转为经鼻高流量氧疗。
  • 经鼻高流量氧疗组流量60 L/min。
  • 主要结局为入组后28天内无呼吸支持天数。

临床怎么用

  • 对于COVID-19中重度低氧性呼吸衰竭患者,头盔无创通气虽未改善主要结局无呼吸支持天数,但可降低气管插管率。
  • 临床决策需权衡头盔无创通气对插管需求的影响与主要结局无显著获益。

局限性

  • 样本量较小(109例),可能影响次要结局的统计效能。
  • 研究仅在意大利4个ICU进行,外部推广性受限。
  • 随访期较短(主要结局28天),长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19. OBJECTIVE: To assess whether helmet noninvasive ventilation can increase the days free of respiratory support in patients with COVID-19 compared with high-flow nasal oxygen alone. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial in 4 intensive care units (ICUs) in Italy between October and December 2020, end of follow-up February 11, 2021, including 109 patients with COVID-19 and moderate to severe hypoxemic respiratory failure (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen ≤200). INTERVENTIONS: Participants were randomly assigned to receive continuous treatment with helmet noninvasive ventilation (positive end-expiratory pressure, 10-12 cm H2O; pressure support, 10-12 cm H2O) for at least 48 hours eventually followed by high-flow nasal oxygen (n = 54) or high-flow oxygen alone (60 L/min) (n = 55). MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days free of respiratory support within 28 days after enrollment. Secondary outcomes included the proportion of patients who required endotracheal intubation within 28 days from study enrollment, the number of days free of invasive mechanical ventilation at day 28, the number of days free of invasive mechanical ventilation at day 60, in-ICU mortality, in-hospital mortality, 28-day mortality, 60-day mortality, ICU length of stay, and hospital length of stay. RESULTS: Among 110 patients who were randomized, 109 (99%) completed the trial (median age, 65 years [interquartile range {IQR}, 55-70]; 21 women [19%]). The median days free of respiratory support within 28 days after randomization were 20 (IQR, 0-25) in the helmet group and 18 (IQR, 0-22) in the high-flow nasal oxygen group, a difference that was not statistically significant (mean difference, 2 days [95% CI, -2 to 6]; P = .26). Of 9 prespecified secondary outcomes reported, 7 showed no significant difference. The rate of endotracheal intubation was significantly lower in the helmet group than in the high-flow nasal oxygen group (30% vs 51%; difference, -21% [95% CI, -38% to -3%]; P = .03). The median number of days free of invasive mechanical ventilation within 28 days was significantly higher in the helmet group than in the high-flow nasal oxygen group (28 [IQR, 13-28] vs 25 [IQR 4-28]; mean difference, 3 days [95% CI, 0-7]; P = .04). The rate of in-hospital mortality was 24% in the helmet group and 25% in the high-flow nasal oxygen group (absolute difference, -1% [95% CI, -17% to 15%]; P > .99). CONCLUSIONS AND RELEVANCE: Among patients with COVID-19 and moderate to severe hypoxemia, treatment with helmet noninvasive ventilation, compared with high-flow nasal oxygen, resulted in no significant difference in the number of days free of respiratory support within 28 days. Further research is warranted to determine effects on other outcomes, including the need for endotracheal intubation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04502576.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Grieco DL, Menga LS, Cesarano M, et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA. 2021. PMID: 33764378. doi:10.1001/jama.2021.4682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。